Vireo Growth (VREOF) Total Current Liabilities (2020 - 2026)
Vireo Growth (VREOF) reported Total Current Liabilities of $215.8 million for Q1 2026, up 56.77% on a YoY basis from $137.7 million in Q1 2025, and up 12.57% sequentially from $191.7 million in Q4 2025.
Vireo Growth (VREOF) Total Current Liabilities (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Total Current Liabilities data on file, last reported at $215.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 56.77% year-over-year to $215.8 million; the trailing twelve-month figure through Mar 2026 stood at $215.8 million (up 56.77% YoY), and the FY2025 full-year result was $191.7 million, up 41.51% from the prior year.
- Total Current Liabilities rose to $215.8 million in Q1 2026, from $191.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $243.5 million in Q2 2025 to a low of $18.5 million in Q2 2022.
- A 5-year average of $138.3 million and a median of $157.0 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 747.46% in 2023 and fell 25.28% in 2025, its largest moves.
- Tracing VREOF's Total Current Liabilities over 5 years: stood at $29.7 million in 2022, then jumped by 504.09% to $179.5 million in 2023, then decreased by 24.52% to $135.5 million in 2024, then soared by 41.51% to $191.7 million in 2025, then advanced by 12.57% to $215.8 million in 2026.
- Business Quant data shows VREOF's Total Current Liabilities at $215.8 million in Q1 2026, $191.7 million in Q4 2025, and $234.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 215.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215.80 Mn |
| Dec 31, 2025 | 191.70 Mn |
| Sep 30, 2025 | 234.91 Mn |
| Jun 30, 2025 | 243.52 Mn |
| Mar 31, 2025 | 137.66 Mn |
| Dec 31, 2024 | 135.47 Mn |
| Sep 30, 2024 | 128.77 Mn |
| Jun 30, 2024 | 186.77 Mn |
| Mar 31, 2024 | 184.24 Mn |
| Dec 31, 2023 | 179.47 Mn |
| Sep 30, 2023 | 165.42 Mn |
| Jun 30, 2023 | 157.00 Mn |
| Mar 31, 2023 | 95.17 Mn |
| Dec 31, 2022 | 29.71 Mn |
| Sep 30, 2022 | 26.35 Mn |
| Jun 30, 2022 | 18.53 Mn |
| Mar 31, 2022 | 20.52 Mn |
| Dec 31, 2021 | 16.41 Mn |
| Sep 30, 2021 | 15.23 Mn |
| Jun 30, 2021 | 16.11 Mn |